|
Gilead Sciences has biotech balms for infectious diseases, including hepatitis, HIV, and infections related to AIDS. The company's HIV franchise includes Truvada, a combination of two of its other drugs, Viread and Emtriva. It co-promotes another HIV treatment, called Atripla, in the US and Europe with Bristol-Myers Squibb (BMS). Other products on the market include AmBisome, used to treat systemic fungal infections such as those that accompany AIDS or kidney disease; Vistide, for AIDS-related eye infections; and hepatitis B antiviral Hepsera. Beyond HIV/AIDS, Gilead also markets cardiovascular drugs Letairis and Ranexa, as well as respiratory and ophthalmic medicines.
|
| | | Contact Information | |
Address: |
333 Lakeside Dr.
Foster City, CA 94404
| | Phone: | 650-574-3000 | | Fax: | 650-578-9264 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2012): | 9702.50 M | | Revenue Growth (1 yr): | 15.70% | | Employees (2012): | 5,000 | | Employee Growth (1 yr): | 11.10% |
|
|
Key People
| | • |
Chairman and CEO:
John C. Martin
| | • |
President and COO:
John F. Milligan
| | • |
SVP and CFO:
Robin L. Washington
|
|
|
